Linking mind with the brain in the study of mental illnesses: a project for scientific psychopathology.
Science 1997;275: 1568–1593.
Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.
Biol Psychiatry 2001;50: 729–942.
Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment.
Br Med Bull 2003;65: 193–207.
Weiler, MAet al. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex.
Neuropsychopharmacol 2004;29 (2):171–178.
Review of longitudinal neuroimaging studies of drug treatments in patients with schizophrenia.
Schizophr Res 2005;78(1):45–60.
Evans, MDet al. Cognitive therapy and pharmacotherapy for depression: singly and in combination.
Arch Gen Psychiatry 1992;49: 774–781.
Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons.
Am J Psychiatry 1999;156: 1007–1013.
One-session treatment for specific phobias.
Behav Res Ther 1989;27: 1–7.
One-session group treatment of spider phobia.
Behav Res Ther 1996;34: 707–715.
Swinson, RP, Specific Phobia. In: Antony, MM and
Swinson, RP, eds. Phobic disorders and panic in adults: a guide to assessment and treatment. Washington, DC: American Psychological Association, 2000: 79–104.
Bressi, Set al. [18F]FDGPET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment.
Br J Psychiatry 1995;166 (2):244–250.
Empirically supported treatments for panic disorder: costs, benefits, and stepped care.
J Consult Clin Psychol 2000;68 (4):556–563.
Cowley, Det al. Practice guideline for the treatment of patients with panic disorder. In: American Psychiatric Association guidelines for the treatment of psychiatric disorders. Compendium 2002: 635–696, American Psychiatric Publishing, Inc., Arlington, VA.
Increased dopamine tone during meditation-induced change of consciousness.
Brain Res Cogn Brain Res 2002;13 (2):255–259.
Approach/withdrawal and cerebral asymmetry: emotional expression and brain physiology. I.
J Pers Soc Psychol 1990;58: 330–341.
Emotion and affective style: hemispheric substrates.
Psychol Sci 1992;3: 39–43.
Schumacher, Jet al. Alterations in brain and immune function produced by mindfulness meditation.
Psychosom Med 2003;65 (4):564–570.
18.Baxter, LR JR,
Bergman, KSet al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder.
Arch Gen Psychiatry 1992;49 (9):681–689.
The practice of behavior therapy. New York: Pergamon Press, 1982.
A critical period for macromolecular synthesis in long-term heterosynaptic facilitation in Aplysia.
Science 1986;234 (4781):1249–1254.
Genes, nerve cells, and the remembrance of things past.
J Neuropsychiatry Clin Neurosci 1989;1 (2):103–125.
Limbic-cortical dysregulation: a proposed model of depression.
J Neuropsychiatry Clin Neurosci 1997;9: 471–481.
A neuroanatomic model for depression.
Prog Neuro-Psychopharmacol Biol Psychiat 1999;23: 175–193.
Prefrontal-subcortical and limbic circuit mediation of major depressive disorder.
Semin Clin Neuropsychiatry 2001;6: 102–112.
Functional neuroimaging studies of depression: the anatomy of melancholia.
Annu Rev Med 1998;49: 341–361.
Prefrontal cortical-amygdalar metabolism in major depression. In: Mcginty, JF, ed.
Advancing from the ventral striatum to the extended amygdala: implications for neuropsychiatry and drug use: in honor of Lennart Heimer. New York: New York Academy of Sciences, 1999: 614–637.
Brannan, SKet al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness.
Am J Psychiatry 1999;156 (5):675–682.
Silverman, DHet al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine.
Psychiatry Res 1999;91 (3):127–139.
Stoessel, Pet al. Brain metabolic changes associated with symptom factor improvement in major depressive disorder.
Biol Psychiatry 2001;50 (3):171–178.
Mahrin, RKet al. Cingulate function in depression: a potential predictor of treatment response.
Neuroreport 1997;8: 1957–1961.
Nitschke, JBet al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis.
Am J Psychiatry 2001;158 (3):405–415.
Stoessel, Pet al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy.
Arch Gen Psychiatry 2001;58: 631–640.
Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings.
Arch Gen Psychiatry 2001;58: 641–648.
Garson, Cet al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.
Arch Gen Psychiatry 2004;61 (1):34–41.
Scientific foundations of cognitive theory and therapy of depression. New York: John Wiley, 1999.
McIntosh, ARet al. Limbic-frontal circuitry in major depression: a path modeling metanalysis.
Neuroimage 2004;22 (1): 409–418.
A neuroanatomical hypothesis for panic disorder.
Am J Psychiatry 1989;146 (2):148–161.
Zalesky, Ret al. The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants.
Neuro Endocrinol Lett 2004;25 (5):340–348.
Greitz, Tet al. Regional cerebral blood flow during experimental phobic fear.
Psychophysiology 1993;30: 126–130.
Functional neuroanatomy of visually elicited simple phobic fear: additional data and theoretical analysis.
Psychophysiology 1995;32: 43–48.
Alpert, NMet al. A positron emission tomographic study of simple phobic symptom provocation.
Arch Gen Psychiatry 1995;52 (1):20–28.
Passant, Uet al. Brain function in spider phobia.
Psychiatry Res 1998;84: 101–111.
Mensour, Bet al. ‘Change the mind and you change the brain’: effects of cognitive-behavioral therapy on the neural correlates of spider phobia.
Neuroimage 2003;18 (2):401–419.
Neuroanatomical hypothesis of panic disorder, revised.
Am J Psychiatry 2000;157 (4):493–505.
45.Baxter, Lr JR,
Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.
Arch Gen Psychiatry 1987;44 (3):211–218.
Obsessive-compulsive disorder: a neuroethological perspective.
Psychopharmacol Bull 1988;24 (3):365–369.
Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder.
J Neuropsychiatry Clin Neurosci 1989;1 (1):27–36.
Recent advances in obsessive-compulsive disorder.
Neuropsychopharmacology 1991;5 (1):1–10.
An update on obsessive-compulsive disorder.
Bull Menninger Clin 2000;65: 4–25.
Baxter, Lr JR,
Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder.
Arch Gen Psychiatry 1996;53 (2):109–113.
Emerging principles of altered neural circuitry in schizophrenia.
Brain Research Reviews 2000;3: 251–269.
Do novel antipsychotics have similar pharmacological characteristics? A review.
Neuropsychopharmacology 1998;18: 63–101.
Differences in frontal cortical activation by a working memory task following substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia.
Proc Nat Acad Sci USA 1999;96 (23):13432–13437.
Mancini-Marie, Aet al. Restoration of frontal activation during a treatment with quetiapine: an fmri study of blunted affect in schizophrenia.
Prog Neuropsychopharmacol Biol Psychiatry 2005;29 (1):21–26.
Cognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies.
Schizophr Res 2000;43 (2–3):71–90.
Cognitive behaviour therapy for schizophrenia.
Cochrane Database Syst Rev 2000;2: cd000524.
Cognitive therapy for psychosis in schizophrenia: an effect size analysis.
Schizophr Res 2001;48 (2–3):335–342.
Kuipers, Eet al. Psychological treatments in schizophrenia. I. Meta-analysis of family intervention and cognitive behaviour therapy.
Psychol Med 2002;32 (5):763–782.
Cognitive-behavioral therapy for schizophrenia: a review.
J Psychiatr Pract 2004;10 (1):5–16.
Fowler, Det al. London-east anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase.
Br J Psychiatry 1997;171: 319–327.
Garety, Pet al. London-east anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: follow-up and economic evaluation at 18 months.
Br J Psychiatry 1998;173: 61–68.
Kinney, Cet al. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia.
BMJ 1998;317: 303–307.
Cognitive-behavioral therapy for medication-resistant symptoms.
Schizophr Bull 2000;26: 73–86.
La Pia, S,
Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia.
Psychiatr Serv 1999;50 (7):91–904.
Kingdon, Det al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication.
Arch Gen Psychiatry 2000;57 (2): 165–172.
Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy.
Psychol Med 2003;33 (3):419–431.
Cognitive therapy for schizophrenia: a preliminary randomized controlled trial.
Schizophr Res 2003;63 (1–2):1–11.
Cognitive behavioral therapy for schizophrenia: an empirical review.
J Nerv Ment Dis 2001;189: 278–287.
North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months.
Psychol Med 2004;34 (3):413–422.
The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis.
Schizophr Res 2005;77 (1):1–9.
Mellers, Jet al. Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia.
Br J Psychiatry 2002;181: 144–152.
The cognitive neuropsychology of schizophrenia. Lea: Hove, 1992.
Willed action and the prefrontal cortex in man: a study with PET.
Proc Biol Sci 1991;244: 241–246.
The perception of self-produced sensory stimuli in patients with auditory hallucinations and passivity experiences: evidence for a breakdown in self-monitoring.
Psychol Med 2000;30 (5):1131–1319.
Frith, Cet al. Verbal self-monitoring and auditory verbal hallucinations in patients with schizophrenia.
Psychol Med 2001;31: 705–715.
Misattribution of external speech in patients with hallucinations and delusions.
Schizophr Res 2004;69 (2–3):277–287.
Action sets and decisions in the medial frontal cortex.
Trends Cogn Sci 2004;8 (9):410–417.
Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study.
Am J Psychiatry 2001;158: 1423–1428.
Kuipers, Eet al. London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. II. Predictors of outcome.
Br J Psychiatry 1997;171: 420–426.
Lou Coad, M,
Mertz, HRet al. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety.
Behav Res Ther 2006;44(5):621–638.
Derbyshire, SWet al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Aliment Pharmacol Ther 2002;16 (7):1357–1366.
Psychopathology in irritable bowel syndrome: support for a psychophysiological model.
J Behav Med 2003;26 (4):361–372.
Abnormal REM sleep in the irritable bowel syndrome.
Gastroenterology 1992;103 (1):12–17.
Systematic review of the comorbidity of irritable bowel syndrome with other disorders. What are the causes and implications? Gastroenterology 2002;122: 1140–1156.
Regional cerebral activity in normal and pathological perception of visceral pain.
Gastroenterology 1997;112: 64–72.
Effects of coping on health outcome among female patients with gastrointestinal disorders.
Psychosom Med 2000;62: 309–317.
Depression and abdominal pain in IBS patients: the mediating role of catastrophizing.
Psychosom Med 2004;66 (3):435–441.
Psychological treatments for irritable bowel syndrome. A systematic review and meta-analysis.
J Consult Clin Psychol 2004;72 (6):1100–1113.
Michelgard, Aet al. Amygdala and anterior cingulate cortex activation during affective startle modulation: a PET study of fear.
Eur J Neurosci 2003;18 (5):1325–1331.
Suyenobu, Bet al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
Gastroenterology 2002;123 (4):969–977.
Stress and irritable bowel syndrome.
Am J Physiol Gastrointest Liver Physiol 2001;280 (4):G519–G524.
Mediators and moderators of treatment effects in randomized clinical trials.
Arch Gen Psychiatry 2002;59 (10):877–883.
Cognitive therapy of depression. New York: Guilford Press, 1979.
Clinical functioning. In: Bandura, A, ed.
Self-efficacy: the exercise of control. New York: Freeman, 1997: 319–368.
Irritable bowel syndrome: psychosocial assessment and treatment. Washington, DC: APA, 2001.